This company has been acquired
Dividendos de Stealth BioTherapeutics
Dividendo controles de criterios 0/6
Información clave
n/a
Rentabilidad por dividendo
n/a
Ratio de pago
Rentabilidad media de la industria | 2.9% |
Próxima fecha de pago de dividendos | n/a |
Fecha ex dividendo | n/a |
Dividendo por acción | n/a |
Beneficios por acción | -US$0.71 |
Rentabilidad por dividendo prevista a 3 años | n/a |
Últimas actualizaciones de dividendos
No hay actualizaciones
Recent updates
Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company
Sep 30Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private
Aug 01Stealth BioTherapeutics: A Net-Net Biopharma Going Private
Jul 26Stealth BioTherapeutics receives Nasdaq non-compliance receipt
Jul 11Stealth Biotherapeutics shares soar on EMA orphan drug status for elamipretide
Jun 01Stealth BioTherapeutics skyrockets on data for elamipretide studies
May 06FDA accepts Stealth Bio's Pre-NDA meeting request for elamipretide
Jan 06Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year
Dec 31Stealth Bio launches $3.2M registered direct offering
Nov 20Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: Insufficient data to determine if MITO's dividends per share have been stable in the past.
Dividendo creciente: Insufficient data to determine if MITO's dividend payments have been increasing.
Rentabilidad por dividendo vs. Mercado
Rentabilidad por dividendo de Stealth BioTherapeutics vs. Mercado |
---|
Segmento | Rentabilidad por dividendo |
---|---|
Empresa (MITO) | n/a |
Suelo de mercado 25% (US) | 1.5% |
Techo de mercado 25% (US) | 4.7% |
Media de la industria (Biotechs) | 2.9% |
Previsión de analistas en 3 años (MITO) | n/a |
Dividendo destacado: Unable to evaluate MITO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Alto dividendo: Unable to evaluate MITO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Pago de beneficios a los accionistas
Cobertura de los beneficios: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: Unable to calculate sustainability of dividends as MITO has not reported any payouts.